Benfotiamine
Also called: S-benzoylthiamine O-monophosphate
A synthetic thiamin (vitamin B1) derivative, S-benzoylthiamine O-monophosphate, used in some dietary supplements. It is not water soluble and is converted to thiamin in the body. General thiamin information is in the thiamin entry.
- Category
- Vitamin
- Forms
- Benfotiamine (S-benzoylthiamine O-monophosphate)
- Strongest evidence
- C Limited
- Reviewed
- 2026-10-30
Class 1 Well studied in people. Ten randomized placebo-controlled trials of oral benfotiamine alone were found: diabetic neuropathy (2005, 2008, 2012, 2020, 2026), diabetic nephropathy (2010), vascular function in type 2 diabetes (2013), Alzheimer's disease (2020), alcohol dependence (2013) and alcoholic polyneuropathy (1998, benfotiamine-alone arm). No systematic review stating a count was found. [3]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CBlood sugar and weight1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Diabetic polyneuropathy symptoms (6-week trial) | C | A 6-week RCT (165 randomized; 300 or 600 mg/day) found improved neuropathy symptom scores per protocol (p = 0.033), slightly above significance in the full ITT population (p = 0.055); total symptom score did not differ. [3] |
| Diabetic polyneuropathy symptoms (3-week pilot) | C | A 3-week randomized, placebo-controlled pilot study (40 patients, 400 mg/day) found a statistically significant improvement in neuropathy score (p = 0.0287), mainly less pain, but no change on the tuning fork test. [2] |
| Diabetic polyneuropathy over 12 months | C | A 12-month double-blind RCT (BOND; 57 people with type 2 diabetes, 300 mg twice daily) found no significant effect on nerve-fiber, neurophysiological or clinical neuropathy measures or quality of life. [4] |
| Kidney damage markers in type 2 diabetic nephropathy | C | A 12-week RCT (82 patients, 900 mg/day, added to ACE inhibitors or ARBs) improved thiamine status but did not reduce urinary albumin or KIM-1 excretion. [5] |
| Cognitive decline in mild cognitive impairment or mild Alzheimer's disease | C | A 12-month phase IIa RCT (70 participants) found a 43% smaller ADAS-Cog increase with benfotiamine (p = 0.125, not significant) and 77% less worsening of clinical dementia rating (p = 0.034). [6] |
| Alcohol consumption in alcohol dependence | C | A 24-week RCT (120 actively drinking adults, 600 mg/day) found alcohol consumption fell in both groups; reductions in total consumption were significantly greater for benfotiamine-treated women. [7] |
Main constituents: Benfotiamine, a synthetic thiamin derivative converted to thiamin in the body [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Studied amounts ranged from 120 to 900 mg/day in diabetic neuropathy and nephropathy trials, with or without other B vitamins (ODS). [1]
- 300 mg twice daily for 12 months (BOND). [4]
- 600 mg once daily for 24 weeks (alcohol dependence). [7]
Upper limits
- The Food and Nutrition Board did not establish a UL for thiamin (ODS). [1]
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications7 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- In the 12-month BOND trial, benfotiamine was well tolerated, with no relevant differences from placebo in rates of adverse events. [4]
- In the 24-week alcohol-dependence trial (600 mg/day), no significant adverse events were noted. [7]
- The 12-month Alzheimer's trial reported benfotiamine treatment was safe. [6]
Regulatory status
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Benfotiamine (S-benzoylthiamine O-monophosphate), converted to thiamin in the body Thiamin (vitamin B1) derivative [P5]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 7 entries naming benfotiamine (S-benzoylthiamine O-monophosphate), one of them a benfotiamine/alpha-lipoic acid combination (earliest NDI 354 submitted 2005-10-11; most recent NDI 681 submitted 2010-12-10). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P1]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P4]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- Xie et al. (2014), healthy Chinese volunteers: compared with thiamine hydrochloride, bioavailability of thiamine in plasma and of thiamine diphosphate in erythrocytes after oral benfotiamine was 1147.3 +/- 490.3% and 195.8 +/- 33.8%; conversion produced large amounts of hippuric acid, without accumulation after multiple doses. [P6]
- ODS: benfotiamine is not water soluble and is converted to thiamin in the body. [P5]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (last update 2026-07-23; checked 2026-10-30), 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-30), 2026-10-30. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (current text, retrieved 2026-10-30), 2026-10-30. ecfr.gov
- NIH Office of Dietary Supplements. Thiamin: Fact Sheet for Health Professionals (Updated: February 9, 2023), 2023-02-09. ods.od.nih.gov
- Xie F, et al. Pharmacokinetic study of benfotiamine and the bioavailability assessment compared to thiamine hydrochloride. J Clin Pharmacol 2014;54(6):688-95 (PMID 24399744), 2014-06. pubmed.ncbi.nlm.nih.gov
Sources
- NIH Office of Dietary Supplements. Thiamin: Fact Sheet for Health Professionals (Updated: February 9, 2023), 2023-02-09. ods.od.nih.gov
- Haupt E, et al. Benfotiamine in the treatment of diabetic polyneuropathy: a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005;43(2):71-7 (PMID 15726875), 2005-02. pubmed.ncbi.nlm.nih.gov
- Stracke H, et al. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008;116(10):600-5 (PMID 18473286), 2008-11. pubmed.ncbi.nlm.nih.gov
- Ziegler D, et al. Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy: a randomized, placebo-controlled, double-blind clinical trial (BOND study). BMJ Open Diabetes Res Care 2026;14(1):e005773 (PMID 41571333), 2026-01-22. pubmed.ncbi.nlm.nih.gov
- Alkhalaf A, et al. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 2010;33(7):1598-601 (PMID 20413516), 2010-07. pubmed.ncbi.nlm.nih.gov
- Gibson GE, et al. Benfotiamine and cognitive decline in Alzheimer's disease: results of a randomized placebo-controlled phase IIa clinical trial. J Alzheimers Dis 2020;78(3):989-1010 (PMID 33074237), 2020. pubmed.ncbi.nlm.nih.gov
- Manzardo AM, et al. Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence. Drug Alcohol Depend 2013;133(2):562-70 (PMID 23992649), 2013-12-01. pubmed.ncbi.nlm.nih.gov
- Fraser DA, et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care 2012;35(5):1095-7 (PMID 22446172), 2012-05. pubmed.ncbi.nlm.nih.gov
- Stirban OA, et al. Treatment with benfotiamine in patients with diabetic sensorimotor polyneuropathy: a double-blind, randomized, placebo-controlled, parallel group pilot study over 12 months. J Diabetes Complications 2020;34(12):107757 (PMID 33069584), 2020-12. pubmed.ncbi.nlm.nih.gov
- Stirban A, et al. A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in type 2 diabetes. Diabet Med 2013;30(10):1204-8 (PMID 23701274), 2013-10. pubmed.ncbi.nlm.nih.gov
- Woelk H, et al. Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAP I Study). Alcohol Alcohol 1998;33(6):631-8 (PMID 9872352), 1998-11. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (Content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in vitamin: Biotin · Folate (folic acid) · Methylfolate (L-5-MTHF) · Niacin (vitamin B3) · Nicotinamide riboside · Pantothenic acid (vitamin B5) · Riboflavin (vitamin B2) · Thiamin (vitamin B1) · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.